Diphenylalanine peptide nanotubes self-assembled on functionalized metal surfaces for potential application in drug-eluting stent

2016 ◽  
Vol 104 (9) ◽  
pp. 2280-2290 ◽  
Author(s):  
Tayebeh Zohrabi ◽  
Neda Habibi ◽  
Ali Zarrabi ◽  
Maryam Fanaei ◽  
Lai Yeng Lee
Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Ho-Wook Jun ◽  
Meenakshi Kushwaha ◽  
Joel Anderson ◽  
William Minor ◽  
Adinarayana Andukuri ◽  
...  

Deployment of stents has been a major therapeutic method for treatment of cardiovascular diseases. However, poor endothelialization and intimal hyperplasia in bare metal stents lead to restenosis. Drug eluting stents (DES) are designed to deliver therapeutic drugs to prevent intimal hyperplasia and have been implanted in about 6 million patients for last three years. However, recent reports suggest that DES have been associated with a higher risk of late thrombosis which may be related to inadequate endothelialization. Therefore, the main goal of this project is to develop the next generation of DES using a natural endothelium mimicking self-assembled nanomatrix which will inhibit both restenosis and thrombosis while enhancing endothelialization from surrounding endothelium and endothelial progenitor cells circulating in the blood stream. The nanomatrix is formed by self-assembly of peptide amphiphiles (PAs) which contain nitric oxide (NO) producing donors and endothelial cell adhesive ligand YIGSR along with enzyme-mediated degradable sites. Successful synthesis of PAs and the self-assembly of the PAs into nanofibers with the diameter of 8 nm forming the nanomatrix were characterized by MALDI-TOF mass spectrometry and transmission electron microscope, respectively. The nanomatrix showed significantly greater attachment and spreading of human umbilical vein endothothelial cells (HUVECs) compared to human aortic smooth muscle cells (AoSMCs). The nanomatrix was reacted with NO solution and NO was released from the nanomatrix rapidly within 24 hours followed by sustained release over period of 5 days. The NO releasing nanomatrix demonstrated a significantly enhanced proliferation of HUVECs (51 ± 3 % to 67 ± 2 %) but reduced proliferation of AoSMCs (35 ± 2 % to 16 ± 3 %) after 48 hrs of incubation. Platelet attachment on the nanomatrix is under investigation. A natural endothelium mimicking nanomatrix was successfully synthesized and supported growth of endothelial cells while inhibiting growth of smooth muscle cells. Therefore this nanomatrix could have a great potential to improve clinical patency of DES as a coating material by enhancing endothelialization but reducing restenosis.


2014 ◽  
Vol 6 (2) ◽  
pp. 107-111
Author(s):  
S Munwar ◽  
AHMW Islam ◽  
S Talukder ◽  
AQM Reza ◽  
T Ahmed ◽  
...  

Background: Aim of the study was to evaluate the primary procedural success of percutaneous coronary intervention of unprotected left main coronary artery stenosis using either Bare-metal stents or drug eluting stent. Methods: Total 33 patients were enrolled in this very preliminary non-randomized prospective cohort study. Among them, Male: 25 and Female: 8. Total 35 stents were deployed. Mean age were for Male: 59 yrs, for Female: 62 yrs. Associated coronary artery diseases risk factors were dyslipidemia, High Blood pressure, Diabetes Mellitus, Positive family history for coronary artery diseases and smoking. Results: Among the study group; 26 (78%) were Dyslipidemic, 24(70%) were hypertensive; 17 (51.5%) patients were Diabetic, 11(33%) were smoker and 7(21%) patients had family history of Ischaemic heart disease. Female patients were more obese (BMI M 26: F 27) and developed coronary artery diseases in advance age. Common stented territory were left main: 20 (60%), Left main to left anterior descending artery 7 (22%) and Left main to left circumflex artery 6 (18%). Average length and diameter of stent was 3.5 and 18 mm respectively. Stent used: Bare Metal Stent 5 (15%), Drug Eluting Stent: 28 (85%). Among the different Drug Eluting Stents, Everolimus eluting stents were 11 (39.3%), Sirolimus eluting 10(35.7%), Paclitaxel eluting 3 (10.7%), Biolimus eluting 3 (10.7%) and Zotarolimus eluting1 (3.6%). In the present study, overall survival outcome was 94% (31 patient), mortality of cardiac cause 3% (1 patient) and 1 patient (3%) died of hepatocellular carcinoma. Conclusion: Our study has shown that percutaneous coronary intervention of the unprotected left main is a safe and effective alternative to Coronary Artery Bypass Graft (CABG). DOI: http://dx.doi.org/10.3329/cardio.v6i2.18349 Cardiovasc. j. 2014; 6(2): 107-111


2006 ◽  
Vol 3 (2) ◽  
pp. 81-82
Author(s):  
Neville Kukreja ◽  
Patrick W Serruys


Author(s):  
Анна Игоревна Простякова ◽  
Дмитрий Игоревич Зыбин ◽  
Дмитрий Валерьевич Капустин

Изучение профиля выделения лекарственного средства in vitro — необходимый этап при оптимизации полимерно-лекарственной композиции в процессе разработки стентов, выделяющих лекарственное вещество (ЛВ). В статье представлены результаты ВЭЖХ-анализа содержания ЛВ и кинетики его выделения из различных типов полимерно-лекарственного покрытия выделяющих ЛВ коронарных стентов (drug eluting stent — DES): биодеградируемого покрытия с сиролимусом и стабильного покрытия с зотаролимусом. Содержание ЛВ оценивали для кримпированных стентов на системе доставки, а также после раскрытия. Продемонстрирована связь морфологии лекарственного покрытия с кинетикой выделения ЛВ и показано, что крупные морфологические дефекты покрытия приводят к отклонению параметров выделения ЛВ.


Sign in / Sign up

Export Citation Format

Share Document